Kawasaki Mayu, Motoyama Tomoharu, Yamada Shoya, Watanabe Masaki, Fujihara Michiko, Kambe Akira, Nakano Shogo, Kakuta Hiroki, Ito Sohei
Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 1-1-1, Tsushima-naka, Kita-ku, Okayama 700-8530, Japan.
ACS Med Chem Lett. 2023 Feb 20;14(3):291-296. doi: 10.1021/acsmedchemlett.2c00509. eCollection 2023 Mar 9.
Retinoid X receptor (RXR), a nuclear receptor (NR) that regulates transcription of target genes in a ligand binding-dependent manner, is of interest as a drug target. RXR agonists have been developed as therapeutic agents for cutaneous invasive T-cell lymphoma (e.g., bexarotene ()) and investigated as potential anti-inflammatory agents. Screening systems for the binding of RXR alone have been reported. However, although RXRs function as RXR heterodimers, information on systems to evaluate the differential binding of RXR agonists as RXR heterodimers has not been available until recently. Here we show that the fluorescent RXR agonist CU-6PMN (), designed by our group, can be useful for assessing RXR binding to PPARγ/RXRα, and that the binding data differ from those of RXRα alone. This screening method opens a new avenue for binding assays for RXR heterodimers.
维甲酸X受体(RXR)是一种核受体(NR),它以配体结合依赖的方式调节靶基因的转录,作为一种药物靶点备受关注。RXR激动剂已被开发为皮肤侵袭性T细胞淋巴瘤的治疗药物(如贝沙罗汀()),并作为潜在的抗炎药物进行了研究。已经报道了单独检测RXR结合的筛选系统。然而,尽管RXR以RXR异二聚体的形式发挥作用,但直到最近,关于评估RXR激动剂作为RXR异二聚体的差异结合的系统信息仍未可得。在此,我们表明,由我们团队设计的荧光RXR激动剂CU-6PMN()可用于评估RXR与PPARγ/RXRα的结合,且结合数据与单独的RXRα不同。这种筛选方法为RXR异二聚体的结合测定开辟了一条新途径。